Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

Intravenous corticosteroid therapy is effective for long-term hair regrowth in alopecia areata, and a scoring system helps predict treatment success and relapse.

Feminizing hormone therapy increases kidney filtration rate.

Targeted testing for telogen effluvium patients can save healthcare costs.

Anifrolumab improves quality of life and reduces steroid use in lupus patients.

JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.

New treatments for severe alopecia areata, especially JAK inhibitors, are recommended as first-line therapy.

The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.

Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.

Increased awareness and research are needed to prevent hair loss from cosmetic procedures.

Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.

Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.

Botulinum toxin might help with some scalp conditions, but more research is needed to confirm its effectiveness and safety.

Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.

Birth control pills and antiandrogens are the most effective medicines for excessive body hair in women, but combining them with other treatments and psychological support is best.

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.

JAK inhibitors offer new hope for treating severe alopecia areata.

The guide helps dermatologists diagnose and treat different types of hair loss.

Early treatment is key for permanent hair loss disorders, with options ranging from medications and phototherapy to immunomodulators and antibiotics, depending on severity and type.

The consensus provided guidelines for treating the Female Athlete Triad and a system to decide when athletes can return to sports.

People with atopic dermatitis have different skin bacteria, and targeting these bacteria might help treat the condition.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.

Cyclosporine is effective for skin conditions but has declined in use due to toxicity concerns.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

Dissolving microneedles show promise for delivering medication through the skin but face challenges like manufacturing complexity and regulatory hurdles.

Blocking the ATX-LPA pathway may improve insulin sensitivity and mitochondrial function in obesity.

COVID-19 patients often experience hair loss and scalp pain, which may be related to the severity of their infection and treatment drugs.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.